‘Heart-in-a-Jar’ Could Save Pharma Companies Billions

The Novoheart is a tiny beating heart-like structure composed of stem cells. It's used for drug testing and is changing the way drugs make it to market.

Novoheart / Image: Novoheart
Novoheart / Image: Novoheart

Taking a drug from initial concept to clinical trial takes about a decade and a billion dollars. A recent CBC News article discussed a new concept: a ‘heart-in-a-jar’ that’s posed to save pharmaceutical companies years of development and a lot of money. The Novoheart is an actual beating heart-like structure made of stem cells that could revolutionize the path to market for new drugs.

Creating the heart valves is a multi-step process where scientists reprogram blood cells into stem cells that are then manipulated into heart cells. Millions of these heart cells form a Jello-O like solution that grows into a mold taking the shape of the “heart.” Once fully formed, the mini heart beats allowing scientists to measure the pace, similar to a heart rate. Pharmaceutical companies have already expressed interest, but Novoheart must file paperwork with the securities regulator before divulging details.

Fresh from the show floor: pharma packaging innovations for 2026
Serialization mandates. Containment demands. Sterile barrier requirements. Our editors found the pharma packaging innovations addressing your biggest challenges at PACK EXPO Las Vegas. Get your free curated report now.
GET YOUR COPY
Fresh from the show floor: pharma packaging innovations for 2026
Recyclable pill bottles are gaining pharmacy ground
Aluminum and paper-based prescription bottles are moving from concept to commercial reality. Here's what pharmacy and packaging leaders need to know.
Read More
Recyclable pill bottles are gaining pharmacy ground